Augmentation of protective immunotherapy against metastatic esb lymphoma-cells by combining immune cell transfer with host irradiation, antigen restimulation and/or anti-tnf-alpha antibody treatment.
To develop effective immunotherapies against disseminated metastatic tumor cells we have tried to improve the overall protective immunity effect by combining adoptive immune cell therapy (ADI) with other treatment modalities. In contrast to other groups who use in vitro cultured effector cells we use for ADI only in situ activated anti-tumor immune cells. The immunotherapy studies were performed with the lymphoma variant ESb which metastasizes to multiple visceral organs and can develop immune escape variants. In the absence of additional exogenous cytokines, peritoneal effector cells (PEC), generated from intra-pinna tumor immunized and i.p. re-stimulated mice, were able to transfer protective immunity and anti-tumor DTH reactivity into syngeneic mice with disseminated ESb tumor cells. We describe the protective immune capacity of PEC in comparison to immune cells from lymph nodes or spleens of immunized mice and test for possible synergistic interactions of the latter with PEC. The adoptive immunotherapy effect seen with immune PEC could be augmented by host irradiation and by combination with active specific immunization (ASI) using previously established virus modified tumor vaccines. In an attempt to study the possible role of cytokines in this system, we tested the effect of neutralizing antibodies to TNF-alpha and IFN-gamma on the therapeutic effect. Anti-TNF-alpha but not anti IFN-gamma antibody treatment augmented the immunotherapeutic effectiveness of immune PEC mediated ADI.